Personalized immunotherapy against several neuronal and brain tumors
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
1. A peptide consisting of the amino acid sequence of SEQ ID NO: 28 wherein said peptide is in the form of a pharmaceutically acceptable salt.
2. The peptide according to claim 1 , wherein said peptide is modified and/or includes non-peptide bonds.
3. The peptide according to claim 1 , capable of being used in medicine.
4. A peptide according to claim 1 , capable of being used for treatment of cancer or in the manufacture of a medicament against cancer.
5. The peptide according to claim 4 , wherein said cancer is selected from astrocytoma, pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor, oligodendrogliomas, ependymoma, glioblastoma multiforme, mixed gliomas, oligoastrocytomas, medulloblastoma, retinoblastoma, neuroblastoma, germinoma, teratoma, gangliogliomas, gangliocytoma, central gangliocytoma, primitive neuroectodermal tumors (PNET, e.g. medulloblastoma, medulloepithelioma, neuroblastoma, retinoblastoma, ependymoblastoma), tumors of the pineal parenchyma (e.g. pineocytoma, pineoblastoma), ependymal cell tumors, choroid plexus tumors, neuroepithelial tumors of uncertain origin (e.g. gliomatosis cerebri, astroblastoma), glioblastoma prostate tumor, breast cancer, esophageal cancer, colorectal cancer, clear cell renal cell carcinoma, lung cancer, CNS, ovarian, melanoma pancreatic cancer, squamous cell carcinoma, leukemia medulloblastoma, colon, rectum, stomach, kidney, lung, pancreas, prostate, skin and other tumors which show an overexpression of COL20A1.
6. A peptide according to claim 4 , wherein said medicament is a vaccine.